Nippon Life Global Investors Americas, Inc. Bristol Myers Squibb CO Transaction History

Nippon Life Global Investors Americas, Inc.

$2.3 Billion
Q3 2024

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 02, 2022	BUY	$72.62 - $79.98 $5.73 Million - $6.32 Million	78,970 New	78,970 $6.08 Million
Q1 2020 May 15, 2020	SELL	$46.4 - $67.43 $3.95 Million - $5.74 Million	-85,070 Closed	0 $0
Q4 2019 Jan 24, 2020	SELL	$49.21 - $64.19 $250,971 - $327,369	-5,100 Reduced 5.66%	85,070 $5.46 Million
Q3 2019 Oct 21, 2019	SELL	$42.77 - $50.71 $771,143 - $914,301	-18,030 Reduced 16.66%	90,170 $4.57 Million
Q2 2019 Jul 23, 2019	BUY	$44.62 - $49.34 $879,460 - $972,491	19,710 Added 22.27%	108,200 $4.91 Million
Q2 2018 Jul 18, 2018	SELL	$50.53 - $62.98 $1.67 Million - $2.08 Million	-33,020 Reduced 27.17%	88,490 $4.9 Million
Q1 2018 May 09, 2018	SELL	$59.92 - $68.98 $12.1 Million - $13.9 Million	-201,760 Reduced 62.41%	121,510 $7.69 Million
Q4 2017 Feb 13, 2018	BUY	$59.94 - $65.35 $553,246 - $603,180	9,230 Added 2.94%	323,270 $19.8 Million
Q3 2017 Nov 13, 2017	BUY	$55.23 - $63.74 $17.3 Million - $20 Million	314,040	314,040 $20 Million

Others Institutions Holding BMY

# of Institutions

2,536

Shares Held

1.47B

Call Options Held

31.6M

Put Options Held

35M

Vanguard Group Inc Valley Forge, PA

189M
Shares

$10.9 Billion
0.18% of portfolio
Black Rock Inc. New York, NY

159M
Shares

$9.16 Billion
0.15% of portfolio
State Street Corp Boston, MA

92.9M
Shares

$5.37 Billion
0.2% of portfolio
Jpmorgan Chase & CO New York, NY

77.9M
Shares

$4.5 Billion
0.33% of portfolio
Charles Schwab Investment Management Inc San Francisco, CA

61M
Shares

$3.53 Billion
0.61% of portfolio

View Full List

About BRISTOL MYERS SQUIBB CO

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $123B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

More about BMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Nippon Life Global Investors Americas, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Nippon Life Global Investors Americas, Inc. with notifications on news.

Account